Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy.
OBJECTIVE
To evaluate the efficacy of latanoprost in reducing acute intraocular pressure (IOP) elevation after neodymium:Yag laser iridotomy (LI).


METHODS
Primary angle-closure glaucoma (PACG) eyes were randomized to receive premedication with latanoprost and pilocarpine or with pilocarpine only before LI. Postoperative IOP changes were compared with Wilcoxon signed-ranks test using the fellow eyes of 47 patients who had one eye in each group.


RESULTS
Postoperative pressure spikes were significantly lower (p = 0.010) in the latanoprost group (4.1 +/- 5.0 mmHg) than in the control group (6.7 +/- 7.0 mmHg). Mean elevation of IOP was less in the latanoprost group than in the control group at 1 hour (2.5 +/- 4.8 versus 4.1 +/- 4.7 mmHg, p = 0.013) and 2 hours (0.8 +/- 5.6 versus 4.4 +/- 8.1 mmHg, p = 0.003) postoperatively. Eleven eyes in the latanoprost group (23.4%) and 20 eyes in the control group (42.6%) developed a rise in IOP > or = 6 mmHg (p = 0.048).


CONCLUSIONS
Latanoprost may reduce the pressure rise following LI in PACG eyes, but its application is limited by a late onset of effect.
Liu
Catherine J
CJ
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. jlliu@vghtpe.gov.tw
Cheng
Ching-Yu
CY
Chiang
Shu-Chiung
SC
Chiu
Allen W
AW
Chou
Joe C K
JC
Hsu
Wen-Ming
WM
Liu
Jorn-Hon
JH
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000601:surgery*; D053685:Laser Therapy / Q000009:adverse effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000209:etiology; D010862:Pilocarpine / Q000627:therapeutic use; D011292:Premedication; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D012449:Safety; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D014792:Visual Acuity
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D010862:Pilocarpine; D000077338:Latanoprost